Reports Q2 revenue $561,574 vs. $249,688 last year. “Aprea continues to make excellent progress advancing its clinical pipeline of therapeutic candidates,” said Oren Gilad, Ph.D., President and Chief Executive Officer of Aprea. “We initiated enrollment in the ACESOT-1051 trial, advancing a second clinical asset in our pipeline, APR-1051. APR-1051 is a next-generation inhibitor of WEE1 kinase which has been designed to limit toxicity. Based on its unique characteristics, we believe it could be best in class. We continue to enroll patients in the ABOYA-119 trial evaluating ATRN-119, our ATR inhibitor. We believe that our ongoing progress positions Aprea at the forefront of synthetic lethality drug development. We remain committed to developing new treatments that have a positive impact on the lives of cancer patients while creating value for our shareholders.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APRE:
- Aprea Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
- Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024
- Aprea Therapeutics announces first patient dosed in ACESOT-1051 Phase I trial
- Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051